Correlation of pretransplant and early post‐transplant response assessment with outcomes after reduced‐intensity allogeneic hematopoietic stem cell transplantation for non‐Hodgkin's lymphoma
BACKGROUND: Chemotherapy sensitivity, defined simply as at least a partial response to chemotherapy, is an important outcome predictor for non‐Hodgkin lymphoma (NHL) patients undergoing reduced‐intensity allogeneic hematopoietic stem cell transplantation (allo‐HCT). The authors hypothesized that fur...
Gespeichert in:
| Veröffentlicht in: | Cancer 2010-02, Vol.116 (4), p.852-862 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 862 |
|---|---|
| container_issue | 4 |
| container_start_page | 852 |
| container_title | Cancer |
| container_volume | 116 |
| creator | Bishop, Michael R. Dean, Robert M. Steinberg, Seth M. Odom, Jeanne Pollack, Seth M. Pavletic, Steven Z. Sportes, Claude Gress, Ronald E. Fowler, Daniel H. |
| description | BACKGROUND:
Chemotherapy sensitivity, defined simply as at least a partial response to chemotherapy, is an important outcome predictor for non‐Hodgkin lymphoma (NHL) patients undergoing reduced‐intensity allogeneic hematopoietic stem cell transplantation (allo‐HCT). The authors hypothesized that further differentiation of chemotherapy sensitivity by specific response, complete remission (CR) versus partial remission (PR) versus stable disease (SD) versus progression of disease (PD), correlates with post‐transplant outcomes.
METHODS:
The impact of pretransplant and early (28 days) post‐transplant disease response on transplant outcomes was analyzed in 63 NHL patients treated with reduced‐intensity allo‐HCT.
RESULTS:
The 3‐year event‐free survival (EFS) and overall survival (OS) (median potential follow‐up after reduced‐intensity allo‐HCT = 58 months) for all patients was 37% and 47%, respectively. The 3‐year EFS based on pretransplant response was: CR = 50%; PR = 66%; SD = 18%; no patient with PD pretransplant reached 3‐year follow‐up. The 3‐year OS based on pretransplant response was: CR = 63%; PR = 69%; SD = 45%. The 3‐year EFS based on post‐transplant response was: CR = 57%; PR = 32%; SD = 33%; no patient with PD post‐transplant reached 3‐year follow‐up. The 3‐year OS based on post‐transplant response was: CR = 65%; PR = 43%; SD = 50%. In multivariate analyses, pretransplant response was the best predictor of EFS (P < .0001). Pretransplant response (P < .0001) and age (P = .0035) were jointly associated with OS.
CONCLUSIONS:
These data suggest that NHL patients with pretransplant SD, generally considered inappropriate candidates, may benefit from reduced‐intensity allo‐HCT, and patients with pretransplant PD should only receive this therapy in clinical trials. Cancer 2010. © 2010 American Cancer Society.
The specific disease response obtained with salvage chemotherapy for relapsed and refractory non‐Hodgkin lymphoma correlates with post‐transplant outcomes in patients being considered for reduced‐intensity allogeneic stem cell transplantation. The differentiation of chemotherapy sensitivity, based on specific responses to salvage chemotherapy, identifies specific patient populations that may or may not benefit from this procedure. |
| doi_str_mv | 10.1002/cncr.24845 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6582966</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>746050545</sourcerecordid><originalsourceid>FETCH-LOGICAL-c4815-b5006da2e4c6712c921690fc7574536092f9a6c7d441bc4752a43bd876f2fc323</originalsourceid><addsrcrecordid>eNp9kc-KFDEQxoMo7jh68QEkF1kQZk3SSf-5CMugrrAoiIK3kElXz0TTSZvKuMzNR_ChfBKfxIwz7q4XT6FSv3xfVT5CHnN2xhkTz22w6UzIVqo7ZMZZ1ywYl-IumTHG2oWS1acT8gDxcykboar75EQwJrlsxYz8XMaUwJvsYqBxoFOCnEzAyZuQqQk9BZP8jk4R86_vP271EuAUAwI1iIA4Qrm7cnlD4zbbOAJSM2RIheu3Fvry2IUMAV3eUeN9XEMAZ-kGRpPjFB3kUmGGkVrwnt44HWYbYqIhhiJzEfv1FxdOkfrdOG3iaB6Se4PxCI-O55x8fPXyw_Jicfnu9Zvl-eXCyparxUoxVvdGgLR1w4XtBK87NthGNVJVNevE0JnaNr2UfGVlo4SR1apvm3oQg61ENScvDrrTdjVCb8vKyXg9JTeatNPROP1vJ7iNXsdvulat6Oq6CJweBVL8ugXMenS4X9cEiFvUjayZYqpMMyfPDqRNETHBcO3Cmd6nrvep6z-pF_jJ7bmu0b8xF-DpETBojR_K31qHN5youqZtWeH4gbtyHnb_sdTLt8v3B_Pf4H7PvQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>746050545</pqid></control><display><type>article</type><title>Correlation of pretransplant and early post‐transplant response assessment with outcomes after reduced‐intensity allogeneic hematopoietic stem cell transplantation for non‐Hodgkin's lymphoma</title><source>Wiley-Blackwell Journals</source><source>MEDLINE</source><source>Free E-Journal (出版社公開部分のみ）</source><source>Wiley Online Library Free Content</source><source>Alma/SFX Local Collection</source><creator>Bishop, Michael R. ; Dean, Robert M. ; Steinberg, Seth M. ; Odom, Jeanne ; Pollack, Seth M. ; Pavletic, Steven Z. ; Sportes, Claude ; Gress, Ronald E. ; Fowler, Daniel H.</creator><creatorcontrib>Bishop, Michael R. ; Dean, Robert M. ; Steinberg, Seth M. ; Odom, Jeanne ; Pollack, Seth M. ; Pavletic, Steven Z. ; Sportes, Claude ; Gress, Ronald E. ; Fowler, Daniel H.</creatorcontrib><description>BACKGROUND:
Chemotherapy sensitivity, defined simply as at least a partial response to chemotherapy, is an important outcome predictor for non‐Hodgkin lymphoma (NHL) patients undergoing reduced‐intensity allogeneic hematopoietic stem cell transplantation (allo‐HCT). The authors hypothesized that further differentiation of chemotherapy sensitivity by specific response, complete remission (CR) versus partial remission (PR) versus stable disease (SD) versus progression of disease (PD), correlates with post‐transplant outcomes.
METHODS:
The impact of pretransplant and early (28 days) post‐transplant disease response on transplant outcomes was analyzed in 63 NHL patients treated with reduced‐intensity allo‐HCT.
RESULTS:
The 3‐year event‐free survival (EFS) and overall survival (OS) (median potential follow‐up after reduced‐intensity allo‐HCT = 58 months) for all patients was 37% and 47%, respectively. The 3‐year EFS based on pretransplant response was: CR = 50%; PR = 66%; SD = 18%; no patient with PD pretransplant reached 3‐year follow‐up. The 3‐year OS based on pretransplant response was: CR = 63%; PR = 69%; SD = 45%. The 3‐year EFS based on post‐transplant response was: CR = 57%; PR = 32%; SD = 33%; no patient with PD post‐transplant reached 3‐year follow‐up. The 3‐year OS based on post‐transplant response was: CR = 65%; PR = 43%; SD = 50%. In multivariate analyses, pretransplant response was the best predictor of EFS (P < .0001). Pretransplant response (P < .0001) and age (P = .0035) were jointly associated with OS.
CONCLUSIONS:
These data suggest that NHL patients with pretransplant SD, generally considered inappropriate candidates, may benefit from reduced‐intensity allo‐HCT, and patients with pretransplant PD should only receive this therapy in clinical trials. Cancer 2010. © 2010 American Cancer Society.
The specific disease response obtained with salvage chemotherapy for relapsed and refractory non‐Hodgkin lymphoma correlates with post‐transplant outcomes in patients being considered for reduced‐intensity allogeneic stem cell transplantation. The differentiation of chemotherapy sensitivity, based on specific responses to salvage chemotherapy, identifies specific patient populations that may or may not benefit from this procedure.</description><identifier>ISSN: 0008-543X</identifier><identifier>EISSN: 1097-0142</identifier><identifier>DOI: 10.1002/cncr.24845</identifier><identifier>PMID: 20041482</identifier><identifier>CODEN: CANCAR</identifier><language>eng</language><publisher>Hoboken: Wiley Subscription Services, Inc., A Wiley Company</publisher><subject>Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols - therapeutic use ; Biological and medical sciences ; chemotherapy sensitivity ; Clinical Trials as Topic ; Cyclophosphamide - therapeutic use ; Disease-Free Survival ; Doxorubicin - therapeutic use ; Etoposide - therapeutic use ; Female ; Hematologic and hematopoietic diseases ; hematopoietic stem cell transplantation ; Hematopoietic Stem Cell Transplantation - methods ; Humans ; Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis ; Lymphoma, Non-Hodgkin - mortality ; Lymphoma, Non-Hodgkin - surgery ; Male ; Medical sciences ; Middle Aged ; nonmyeloablative ; non‐Hodgkin lymphoma ; Postoperative Period ; Prednisone - therapeutic use ; Preoperative Period ; reduced‐intensity ; Survival Rate ; Transplantation Conditioning ; Transplantation, Autologous ; Treatment Outcome ; Tumors ; Vincristine - therapeutic use</subject><ispartof>Cancer, 2010-02, Vol.116 (4), p.852-862</ispartof><rights>Copyright © 2010 American Cancer Society</rights><rights>2015 INIST-CNRS</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c4815-b5006da2e4c6712c921690fc7574536092f9a6c7d441bc4752a43bd876f2fc323</citedby><cites>FETCH-LOGICAL-c4815-b5006da2e4c6712c921690fc7574536092f9a6c7d441bc4752a43bd876f2fc323</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1002%2Fcncr.24845$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1002%2Fcncr.24845$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>230,314,780,784,885,1417,1433,27924,27925,45574,45575,46409,46833</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=22397880$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/20041482$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Bishop, Michael R.</creatorcontrib><creatorcontrib>Dean, Robert M.</creatorcontrib><creatorcontrib>Steinberg, Seth M.</creatorcontrib><creatorcontrib>Odom, Jeanne</creatorcontrib><creatorcontrib>Pollack, Seth M.</creatorcontrib><creatorcontrib>Pavletic, Steven Z.</creatorcontrib><creatorcontrib>Sportes, Claude</creatorcontrib><creatorcontrib>Gress, Ronald E.</creatorcontrib><creatorcontrib>Fowler, Daniel H.</creatorcontrib><title>Correlation of pretransplant and early post‐transplant response assessment with outcomes after reduced‐intensity allogeneic hematopoietic stem cell transplantation for non‐Hodgkin's lymphoma</title><title>Cancer</title><addtitle>Cancer</addtitle><description>BACKGROUND:
Chemotherapy sensitivity, defined simply as at least a partial response to chemotherapy, is an important outcome predictor for non‐Hodgkin lymphoma (NHL) patients undergoing reduced‐intensity allogeneic hematopoietic stem cell transplantation (allo‐HCT). The authors hypothesized that further differentiation of chemotherapy sensitivity by specific response, complete remission (CR) versus partial remission (PR) versus stable disease (SD) versus progression of disease (PD), correlates with post‐transplant outcomes.
METHODS:
The impact of pretransplant and early (28 days) post‐transplant disease response on transplant outcomes was analyzed in 63 NHL patients treated with reduced‐intensity allo‐HCT.
RESULTS:
The 3‐year event‐free survival (EFS) and overall survival (OS) (median potential follow‐up after reduced‐intensity allo‐HCT = 58 months) for all patients was 37% and 47%, respectively. The 3‐year EFS based on pretransplant response was: CR = 50%; PR = 66%; SD = 18%; no patient with PD pretransplant reached 3‐year follow‐up. The 3‐year OS based on pretransplant response was: CR = 63%; PR = 69%; SD = 45%. The 3‐year EFS based on post‐transplant response was: CR = 57%; PR = 32%; SD = 33%; no patient with PD post‐transplant reached 3‐year follow‐up. The 3‐year OS based on post‐transplant response was: CR = 65%; PR = 43%; SD = 50%. In multivariate analyses, pretransplant response was the best predictor of EFS (P < .0001). Pretransplant response (P < .0001) and age (P = .0035) were jointly associated with OS.
CONCLUSIONS:
These data suggest that NHL patients with pretransplant SD, generally considered inappropriate candidates, may benefit from reduced‐intensity allo‐HCT, and patients with pretransplant PD should only receive this therapy in clinical trials. Cancer 2010. © 2010 American Cancer Society.
The specific disease response obtained with salvage chemotherapy for relapsed and refractory non‐Hodgkin lymphoma correlates with post‐transplant outcomes in patients being considered for reduced‐intensity allogeneic stem cell transplantation. The differentiation of chemotherapy sensitivity, based on specific responses to salvage chemotherapy, identifies specific patient populations that may or may not benefit from this procedure.</description><subject>Adult</subject><subject>Aged</subject><subject>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</subject><subject>Biological and medical sciences</subject><subject>chemotherapy sensitivity</subject><subject>Clinical Trials as Topic</subject><subject>Cyclophosphamide - therapeutic use</subject><subject>Disease-Free Survival</subject><subject>Doxorubicin - therapeutic use</subject><subject>Etoposide - therapeutic use</subject><subject>Female</subject><subject>Hematologic and hematopoietic diseases</subject><subject>hematopoietic stem cell transplantation</subject><subject>Hematopoietic Stem Cell Transplantation - methods</subject><subject>Humans</subject><subject>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</subject><subject>Lymphoma, Non-Hodgkin - mortality</subject><subject>Lymphoma, Non-Hodgkin - surgery</subject><subject>Male</subject><subject>Medical sciences</subject><subject>Middle Aged</subject><subject>nonmyeloablative</subject><subject>non‐Hodgkin lymphoma</subject><subject>Postoperative Period</subject><subject>Prednisone - therapeutic use</subject><subject>Preoperative Period</subject><subject>reduced‐intensity</subject><subject>Survival Rate</subject><subject>Transplantation Conditioning</subject><subject>Transplantation, Autologous</subject><subject>Treatment Outcome</subject><subject>Tumors</subject><subject>Vincristine - therapeutic use</subject><issn>0008-543X</issn><issn>1097-0142</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2010</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kc-KFDEQxoMo7jh68QEkF1kQZk3SSf-5CMugrrAoiIK3kElXz0TTSZvKuMzNR_ChfBKfxIwz7q4XT6FSv3xfVT5CHnN2xhkTz22w6UzIVqo7ZMZZ1ywYl-IumTHG2oWS1acT8gDxcykboar75EQwJrlsxYz8XMaUwJvsYqBxoFOCnEzAyZuQqQk9BZP8jk4R86_vP271EuAUAwI1iIA4Qrm7cnlD4zbbOAJSM2RIheu3Fvry2IUMAV3eUeN9XEMAZ-kGRpPjFB3kUmGGkVrwnt44HWYbYqIhhiJzEfv1FxdOkfrdOG3iaB6Se4PxCI-O55x8fPXyw_Jicfnu9Zvl-eXCyparxUoxVvdGgLR1w4XtBK87NthGNVJVNevE0JnaNr2UfGVlo4SR1apvm3oQg61ENScvDrrTdjVCb8vKyXg9JTeatNPROP1vJ7iNXsdvulat6Oq6CJweBVL8ugXMenS4X9cEiFvUjayZYqpMMyfPDqRNETHBcO3Cmd6nrvep6z-pF_jJ7bmu0b8xF-DpETBojR_K31qHN5youqZtWeH4gbtyHnb_sdTLt8v3B_Pf4H7PvQ</recordid><startdate>20100215</startdate><enddate>20100215</enddate><creator>Bishop, Michael R.</creator><creator>Dean, Robert M.</creator><creator>Steinberg, Seth M.</creator><creator>Odom, Jeanne</creator><creator>Pollack, Seth M.</creator><creator>Pavletic, Steven Z.</creator><creator>Sportes, Claude</creator><creator>Gress, Ronald E.</creator><creator>Fowler, Daniel H.</creator><general>Wiley Subscription Services, Inc., A Wiley Company</general><general>Wiley-Blackwell</general><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7T5</scope><scope>H94</scope><scope>5PM</scope></search><sort><creationdate>20100215</creationdate><title>Correlation of pretransplant and early post‐transplant response assessment with outcomes after reduced‐intensity allogeneic hematopoietic stem cell transplantation for non‐Hodgkin's lymphoma</title><author>Bishop, Michael R. ; Dean, Robert M. ; Steinberg, Seth M. ; Odom, Jeanne ; Pollack, Seth M. ; Pavletic, Steven Z. ; Sportes, Claude ; Gress, Ronald E. ; Fowler, Daniel H.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c4815-b5006da2e4c6712c921690fc7574536092f9a6c7d441bc4752a43bd876f2fc323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2010</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Antineoplastic Combined Chemotherapy Protocols - therapeutic use</topic><topic>Biological and medical sciences</topic><topic>chemotherapy sensitivity</topic><topic>Clinical Trials as Topic</topic><topic>Cyclophosphamide - therapeutic use</topic><topic>Disease-Free Survival</topic><topic>Doxorubicin - therapeutic use</topic><topic>Etoposide - therapeutic use</topic><topic>Female</topic><topic>Hematologic and hematopoietic diseases</topic><topic>hematopoietic stem cell transplantation</topic><topic>Hematopoietic Stem Cell Transplantation - methods</topic><topic>Humans</topic><topic>Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis</topic><topic>Lymphoma, Non-Hodgkin - mortality</topic><topic>Lymphoma, Non-Hodgkin - surgery</topic><topic>Male</topic><topic>Medical sciences</topic><topic>Middle Aged</topic><topic>nonmyeloablative</topic><topic>non‐Hodgkin lymphoma</topic><topic>Postoperative Period</topic><topic>Prednisone - therapeutic use</topic><topic>Preoperative Period</topic><topic>reduced‐intensity</topic><topic>Survival Rate</topic><topic>Transplantation Conditioning</topic><topic>Transplantation, Autologous</topic><topic>Treatment Outcome</topic><topic>Tumors</topic><topic>Vincristine - therapeutic use</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Bishop, Michael R.</creatorcontrib><creatorcontrib>Dean, Robert M.</creatorcontrib><creatorcontrib>Steinberg, Seth M.</creatorcontrib><creatorcontrib>Odom, Jeanne</creatorcontrib><creatorcontrib>Pollack, Seth M.</creatorcontrib><creatorcontrib>Pavletic, Steven Z.</creatorcontrib><creatorcontrib>Sportes, Claude</creatorcontrib><creatorcontrib>Gress, Ronald E.</creatorcontrib><creatorcontrib>Fowler, Daniel H.</creatorcontrib><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Immunology Abstracts</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Bishop, Michael R.</au><au>Dean, Robert M.</au><au>Steinberg, Seth M.</au><au>Odom, Jeanne</au><au>Pollack, Seth M.</au><au>Pavletic, Steven Z.</au><au>Sportes, Claude</au><au>Gress, Ronald E.</au><au>Fowler, Daniel H.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Correlation of pretransplant and early post‐transplant response assessment with outcomes after reduced‐intensity allogeneic hematopoietic stem cell transplantation for non‐Hodgkin's lymphoma</atitle><jtitle>Cancer</jtitle><addtitle>Cancer</addtitle><date>2010-02-15</date><risdate>2010</risdate><volume>116</volume><issue>4</issue><spage>852</spage><epage>862</epage><pages>852-862</pages><issn>0008-543X</issn><eissn>1097-0142</eissn><coden>CANCAR</coden><abstract>BACKGROUND:
Chemotherapy sensitivity, defined simply as at least a partial response to chemotherapy, is an important outcome predictor for non‐Hodgkin lymphoma (NHL) patients undergoing reduced‐intensity allogeneic hematopoietic stem cell transplantation (allo‐HCT). The authors hypothesized that further differentiation of chemotherapy sensitivity by specific response, complete remission (CR) versus partial remission (PR) versus stable disease (SD) versus progression of disease (PD), correlates with post‐transplant outcomes.
METHODS:
The impact of pretransplant and early (28 days) post‐transplant disease response on transplant outcomes was analyzed in 63 NHL patients treated with reduced‐intensity allo‐HCT.
RESULTS:
The 3‐year event‐free survival (EFS) and overall survival (OS) (median potential follow‐up after reduced‐intensity allo‐HCT = 58 months) for all patients was 37% and 47%, respectively. The 3‐year EFS based on pretransplant response was: CR = 50%; PR = 66%; SD = 18%; no patient with PD pretransplant reached 3‐year follow‐up. The 3‐year OS based on pretransplant response was: CR = 63%; PR = 69%; SD = 45%. The 3‐year EFS based on post‐transplant response was: CR = 57%; PR = 32%; SD = 33%; no patient with PD post‐transplant reached 3‐year follow‐up. The 3‐year OS based on post‐transplant response was: CR = 65%; PR = 43%; SD = 50%. In multivariate analyses, pretransplant response was the best predictor of EFS (P < .0001). Pretransplant response (P < .0001) and age (P = .0035) were jointly associated with OS.
CONCLUSIONS:
These data suggest that NHL patients with pretransplant SD, generally considered inappropriate candidates, may benefit from reduced‐intensity allo‐HCT, and patients with pretransplant PD should only receive this therapy in clinical trials. Cancer 2010. © 2010 American Cancer Society.
The specific disease response obtained with salvage chemotherapy for relapsed and refractory non‐Hodgkin lymphoma correlates with post‐transplant outcomes in patients being considered for reduced‐intensity allogeneic stem cell transplantation. The differentiation of chemotherapy sensitivity, based on specific responses to salvage chemotherapy, identifies specific patient populations that may or may not benefit from this procedure.</abstract><cop>Hoboken</cop><pub>Wiley Subscription Services, Inc., A Wiley Company</pub><pmid>20041482</pmid><doi>10.1002/cncr.24845</doi><tpages>11</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0008-543X |
| ispartof | Cancer, 2010-02, Vol.116 (4), p.852-862 |
| issn | 0008-543X 1097-0142 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6582966 |
| source | Wiley-Blackwell Journals; MEDLINE; Free E-Journal (出版社公開部分のみ）; Wiley Online Library Free Content; Alma/SFX Local Collection |
| subjects | Adult Aged Antineoplastic Combined Chemotherapy Protocols - therapeutic use Biological and medical sciences chemotherapy sensitivity Clinical Trials as Topic Cyclophosphamide - therapeutic use Disease-Free Survival Doxorubicin - therapeutic use Etoposide - therapeutic use Female Hematologic and hematopoietic diseases hematopoietic stem cell transplantation Hematopoietic Stem Cell Transplantation - methods Humans Leukemias. Malignant lymphomas. Malignant reticulosis. Myelofibrosis Lymphoma, Non-Hodgkin - mortality Lymphoma, Non-Hodgkin - surgery Male Medical sciences Middle Aged nonmyeloablative non‐Hodgkin lymphoma Postoperative Period Prednisone - therapeutic use Preoperative Period reduced‐intensity Survival Rate Transplantation Conditioning Transplantation, Autologous Treatment Outcome Tumors Vincristine - therapeutic use |
| title | Correlation of pretransplant and early post‐transplant response assessment with outcomes after reduced‐intensity allogeneic hematopoietic stem cell transplantation for non‐Hodgkin's lymphoma |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T07%3A43%3A54IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Correlation%20of%20pretransplant%20and%20early%20post%E2%80%90transplant%20response%20assessment%20with%20outcomes%20after%20reduced%E2%80%90intensity%20allogeneic%20hematopoietic%20stem%20cell%20transplantation%20for%20non%E2%80%90Hodgkin's%20lymphoma&rft.jtitle=Cancer&rft.au=Bishop,%20Michael%20R.&rft.date=2010-02-15&rft.volume=116&rft.issue=4&rft.spage=852&rft.epage=862&rft.pages=852-862&rft.issn=0008-543X&rft.eissn=1097-0142&rft.coden=CANCAR&rft_id=info:doi/10.1002/cncr.24845&rft_dat=%3Cproquest_pubme%3E746050545%3C/proquest_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=746050545&rft_id=info:pmid/20041482&rfr_iscdi=true |